Short-term side effects of low dose valproate monotherapy in epileptic children: a prospective study
Iranian Journal of Child Neurology,
Vol. 13 No. 2 (2019),
4 March 2019
,
Page 37-46
https://doi.org/10.22037/ijcn.v13i2.16652
Abstract
Objectives: Considering the common use of valproate among children, we investigated short-term side-effects of low dose valproate monotherapy in epileptic children.
Materials and Methods: In this prospective study, 209 epileptic children (48.3% male, mean age: 7.02 ± 3.13 years) on low therapeutic dose of valproate monotherapy (20-30 mg/Kg/daily) were enrolled and side-effects were evaluated through frequent clinical visits and laboratory tests during 6 months.
Results: Weight gain was reported in 53.1% of patients. Decreased appetite was seen in 11% of patients, more frequent in younger cases (P=0.006). Abdominal pain, nausea/vomiting, diarrhea, and constipation were reported in 16.3%, 2.4%, 1.4%, and 1% of patients, respectively. Headache, tremor, dizziness, abnormal color vision, myoclonus, and bruxism were seen in 5.7%, 1.4%, 1%, 1%, 1%, and 0.5% of patients, respectively. Enuresis, hair loss, and skin rash were reported in 8.1%, 6.7%, and 0.5% of patients, respectively. Thrombocytopenia, impaired liver function tests, and leukopenia occurred in 1%, 1%, and 0.5% of patients, respectively.
Conclusions: low dose valproate monotherapy may cause numerous side-effects, mostly not life-threatening and requiring no action. Besides more reported complications, we observed decreased appetite (among younger patients), enuresis, and abnormal color vision which have been briefly discussed in the literature and need to be addressed more.
- Adverse drug reactions
- Epilepsy
- Pediatrics
- Valproate monotherapy
How to Cite
References
Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clinical biochemistry. 2013;46(15):1323-38.
Dugbartey AT, Barimah KB. Traditional beliefs and knowledge base about epilepsy among university students in Ghana. Ethnicity & disease. 2012;23:1-5.
Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert opinion on drug metabolism & toxicology. 2012;8(1):81-91.
Dols A, Sienaert P, van Gerven H, Schouws S, Stevens A, Kupka R, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. International clinical psychopharmacology. 2013;28:287-96.
Gerstner T, Bauer MO, Longin E, Bell N, Koenig SA. Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2-year-old girl. Seizure. 2007;16(6):554-6.
Zerjav S, Stowe R. Serious neurological complications of valproate therapy. Psychopharmacol Newslett. 2007:1-5.
Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-63.
De Onis M. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: WHO; 2006.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics. 1981;30(2):239-45.
Ghofrani M, Tonekaboni SH, Aminzadeh V, Abadi FMS. SODIUM VALPROATE AND PHENOBARBITOL: WEIGHT COMPLICATIONS OF TREATMENT IN EPILEPTIC CHILDREN. Iranian Journal of Child Neurology. 2008;2:15-8.
Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatric neurology. 2003;28(2):126-9.
Sharpe C, Wolfson T, Trauner DA. Weight gain in children treated with valproate. Journal of child neurology. 2009;24(3):338-41.
Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. The Annals of pharmacotherapy. 2009;43(1):45-50.
Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. Journal of child neurology. 1999;14(8):490-5.
Kanemura H, Sano F, Maeda Y, Sugita K, Aihara M. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure. 2012;21(7):496-500.
Jahromi SR, Togha M, Fesharaki SH, Najafi M, Moghadam NB, Kheradmand JA, et al. Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients. Seizure. 2011;20(4):343-6.
Yu PM, Zhu GX, Wu XY, Li T, Xu L, Yue L, et al. A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy. Seizure. 2011;20(1):23-6.
Yamak WR, Hmaimess G, Makke Y, Sabbagh S, Arabi M, Beydoun A, et al. Valproate-induced enuresis: a prospective study. Developmental medicine and child neurology. 2015;57(8):737-41.
Hajishengallis E. Psychotropic drugs and their impact on the treatment of paediatric dental patients. European Archives of Paediatric Dentistry. 2013;14:197-206.
Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. British medical journal. 1981;283(6291):577-81.
Ramakrishnappa SK, Belhekar MN. Serum drug level-related sodium valproate-induced hair loss. Indian journal of pharmacology. 2013;45(2):187-8.
Chang Y-C, Lin J-J, Wang H-S, Chou M-L, Hung P-C, Hsieh M-Y, et al. Intravenous valproate for seizures in 137 Taiwanese children-valproate naive and non-naive. Acta Neurol Taiwan. 2010;19:100-6.
Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS drugs. 2010;24(6):501-26.
Verrotti A, Lobefalo L, Priolo T, Rapinese M, Trotta D, Morgese G, et al. Color vision in epileptic adolescents treated with valproate and carbamazepine. Seizure. 2004;13(6):411-7.
Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47(7):1136-43.
Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2008;19(5):375-82.
Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438-45.
Chakraborty S, Chakraborty J, Mandal S, Ghosal MK. A rare occurrence of isolated neutropenia with valproic acid: a case report. Journal of the Indian Medical Association. 2011;109(5):345-6.
Ghozzi H, Hakim A, Sahnoun Z, Ben ML, Atheymen R, Hammami S, et al. [Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses]. Revue neurologique. 2010;167:600-6.
Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. British journal of clinical pharmacology. 2010;70(5):721-8.
- Abstract Viewed: 434 times